Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Giulia Martina Cavestro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1947-9368; OpenAlex author ID A5032074249. Sources: OpenAlex.

Their work

Papers
38 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
133
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 2 papers · 2021: 9 papers · 2022: 1 paper · 2023: 6 papers · 2024: 4 papers · 2025: 2 papers · 2026: 5 papers

Papers 38

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  3. Novel approaches to liquid biopsy in pancreatic cancer. Last author DOI 10.1016/j.dld.2026.06.008↗
  4. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  5. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  6. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  7. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  8. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Co-author DOI 10.1002/cncr.35383↗
  9. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  10. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  11. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  12. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  13. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  14. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  15. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  16. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  17. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  18. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  19. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  20. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  21. Low-frequency of RABL3 pathogenetic variants in hereditary and familial pancreatic cancer. Last author DOI 10.1016/j.dld.2020.11.024↗
  22. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  23. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  24. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  25. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  26. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  27. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  28. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  29. MSH6 gene pathogenic variant identified in familial pancreatic cancer in the absence of colon cancer. Last author DOI 10.1097/meg.0000000000001617↗
  30. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  31. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  32. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Regis… Co-author DOI 10.1038/s41395-018-0414-z↗
  33. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  34. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  35. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  36. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  37. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  38. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗

Closest collaborators

The 25 strongest of 133 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marta Puzzono · 7 shared papers, 2021–2026 · strength 1.28
  2. Alessandro Mannucci · 6 shared papers, 2019–2026 · strength 1.05
  3. Paolo Giorgio Arcidiacono · 5 shared papers, 2021–2026 · strength 0.95
  4. Gabriele Capurso · 8 shared papers, 2019–2026 · strength 0.94
  5. Massimo Falconi · 5 shared papers, 2019–2026 · strength 0.73
  6. Lívia Archibugi · 5 shared papers, 2022–2026 · strength 0.71
  7. Salvatore Paiella · 4 shared papers, 2019–2026 · strength 0.58
  8. Roberto Salvia · 4 shared papers, 2019–2026 · strength 0.58
  9. Raffaele Pezzilli · 6 shared papers, 2019–2024 · strength 0.56
  10. Erica Secchettin · 3 shared papers, 2024–2026 · strength 0.50
  11. Giuliana Sereni · 3 shared papers, 2024–2026 · strength 0.50
  12. Arianna Dal Buono · 3 shared papers, 2024–2026 · strength 0.50
  13. Silvia Carrara · 4 shared papers, 2019–2026 · strength 0.49
  14. Alessandro Zerbi · 3 shared papers, 2019–2026 · strength 0.40
  15. Luigi Laghi · 3 shared papers, 2019–2026 · strength 0.40
  16. John S. Bolton · 2 shared papers, 2026 · strength 0.39
  17. Caiming Xu · 2 shared papers, 2026 · strength 0.39
  18. Mitsuro Kanda · 2 shared papers, 2026 · strength 0.39
  19. Derek Cridebring · 2 shared papers, 2026 · strength 0.39
  20. Laleh Golkar Melstrom · 2 shared papers, 2026 · strength 0.39
  21. Scott A. Celinski · 2 shared papers, 2026 · strength 0.39
  22. Eunsung Jun · 2 shared papers, 2026 · strength 0.39
  23. Carlos Roberto Becerra · 2 shared papers, 2026 · strength 0.39
  24. Douglas B. Evans · 2 shared papers, 2026 · strength 0.39
  25. Haiyong Han · 2 shared papers, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.